Lataa...
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
While the modest reduction in the primary composite outcome of myocardial infarction, stroke or cardiovascular death in the EMPA-REG Outcomes trial was welcome, the 30–40% reductions in heart failure hospitalisation (HFH) and cardiovascular and all-cause deaths in patients treated with empagliflozin...
Tallennettuna:
| Julkaisussa: | Diabetologia |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer Berlin Heidelberg
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4901113/ https://ncbi.nlm.nih.gov/pubmed/27112340 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-016-3956-x |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|